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Safety and eﬃcacy of oral fexofenadine in
children with seasonal allergic rhinitis –
a pooled analysis of three studies
Allergic rhinitis is one of the most common
chronic conditions in childhood (1). In partic-
ular, many children who develop allergies to
inhalant allergens in early life are at an increased
risk of developing seasonal allergic rhinitis
(SAR) and asthma in later childhood. This
chronological progression of clinical manifesta-
tions of allergy is termed the allergic march.
Besides the potential serious implications of
leading to asthma and other symptoms, children
with untreated allergy symptoms have been
shown to exhibit poorer learning ability com-
pared with non-allergic children (2). Moreover,
data indicate that almost a million school days
are missed per year as a direct result of allergic
rhinitis in the USA (3). Estimates of its preval-
ence in children, which vary from country to
country, have been reported to be as high as 40%
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Allergic rhinitis is one of the most common clinical conditions in chil-
dren; however, data regarding the safety of antihistamines in children
with seasonal allergic rhinitis are limiting. To evaluate the safety and
eﬃcacy of fexofenadine in children with seasonal allergic rhinitis, data
were pooled from three, double-blind, randomized, placebo-controlled,
parallel-group, 2-week trials in children (6–11 year) with seasonal
allergic rhinitis. All studies assessed fexofenadine HCl 30 mg b.i.d.; two
studies included fexofenadine HCl at 15 and 60 mg b.i.d. Patients (and
investigators) reported any adverse events during the trial. Physical
examinations, including measurements of vital signs and laboratory
tests, were performed. Eﬃcacy assessments (total symptom score and
individual symptom scores) were evaluated. Exposure to fexofenadine
HCl 30 mg b.i.d. and to any fexofenadine dose exceeded 10,000 and
17,000 patient days, respectively. Incidences of adverse events, and
discontinuations because of adverse events, were low and similar across
treatment groups. In the placebo group, 24.4% of subjects reported
adverse events compared with 24.1% for fexofenadine HCl 30 mg b.i.d.,
and 28.4% for all fexofenadine-treated groups. The most common ad-
verse event overall was headache (4.3% placebo; 5.8% fexofenadine
HCl 30 mg b.i.d.; and 7.2% any fexofenadine doses). Treatment-related
adverse events were similar across treatment groups with no sedative
eﬀects. Fexofenadine HCl 30 mg b.i.d. was signiﬁcantly superior to
placebo in reducing the total symptom score and all individual seasonal
allergic rhinitis symptoms, including nasal congestion (p < 0.05).
Fexofenadine, at doses of up to 60 mg b.i.d., is safe and non-sedating,
and fexofenadine HCl 30 mg b.i.d. eﬀectively reduces all seasonal
allergic rhinitis symptoms in children aged 6–11 years.
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(4), and it appears that the incidence of allergic
rhinitis in this patient population is rising (5).
Since 1942, antihistamines have been used as
ﬁrst-line treatment for SAR in patients of all ages
(6–8). However, results from studies using ﬁrst-
generation antihistamines have demonstrated
signiﬁcant adverse eﬀects as a result of their
sedative eﬀects, resulting in impairment of psy-
chomotor and academic function in children (2).
Fexofenadine (Allegra/Telfast, Aventis Phar-
maceuticals, Kansas City, MO, USA), an optimal
second generation antihistamine, demonstrates
greater selectivity for the H1-receptor and lacks
the anti-cholinergic and sedating adverse eﬀects
associated with many of the older antihistamines
(9). Fexofenadine has been approved for the
treatment of SAR and chronic idiopathic urtic-
aria in adults, and large, randomized trials have
demonstrated the eﬃcacy and safety of this agent
in adult populations (10–14). Furthermore,
results of dose–response trials in healthy adults
show that doses of up to 690 mg b.i.d. admin-
istered for 1 month are safe and well-tolerated
(15, 16). However, despite the greater emphasis
on safety and tolerability in this population, data
regarding the safety of antihistamines in children
in controlled studies are limited. A previous
report by Graft et al. (17) showed that doses of
fexofenadine HCl, up to 60 mg b.i.d., are safe
and well-tolerated in children aged 6–11 years,
with no dose-related trends. In addition, a recent,
worldwide study reported the eﬃcacy and safety
of fexofenadine HCl (30 mg b.i.d.) in children
aged 6–11 years with SAR (18).
In order to further evaluate the safety of the
recommended fexofenadine dose in this popula-
tion, the safety results of these studies have been
pooled. In addition, the eﬃcacy of fexofenadine




Three trials (studies I–III) were included in the
pooled safety analysis. Children aged 6–
11 years, with spring or fall SAR, and a history
of SAR of approximately 1 year or more during
at least one previous relevant season, were
enrolled. Subjects were required to have a
positive skin-prick test (wheal diameter ‡3 mm
than that with diluent within 15 min of the skin
prick) to at least one allergen for the current
season. To facilitate objective characterization
of the subject’s allergies, patients in study I also
required the presence of an allergen-speciﬁc
immunoglobulin E (IgE) that was positive in
the skin-prick test.
Excluded patients were (but were not limited
to) those with a respiratory tract nasal infection,
sinusitis, or otitis media within 30 days of study
entry; clinically signiﬁcant cardiovascular, hep-
atic, neurologic, psychiatric, endocrine or other
major systemic disease; or immunotherapy treat-
ment.
Written informed consent from a parent/
guardian and each child was obtained before
inclusion in the study.
Study design
Studies I–III were double-blind, randomized,
placebo-controlled, parallel-group, 2-wk trials.
All three studies had a similar design with
regard to patient selection criteria and, primary
and secondary outcome measures. Study I was
conducted at 148 centers in 15 countries:
Argentina (16), Australia (nine), Austria (one),
Chile (three), Finland (three), France (12),
Germany (ﬁve), Israel (three), Italy (seven),
Poland (10), Portugal (two), South Africa (18),
Spain (six), Uruguay (two) and the USA (51)
(18). Studies II and III were identical trials
conducted at 58 investigative sites in the USA
and Canada (17).
All three trials had a similar study design. At
visit 1 (baseline), the children (with the help of
their caregiver) provided a 12-hour reﬂective
assessment of the severity of their allergy symp-
toms. Seasonal allergic rhinitis symptom scores
were recorded for sneezing; rhinorrhea; itchy
nose, palate, throat and/or ears; itchy, watery
and/or red eyes; and nasal congestion. Each
symptom was evaluated on a ﬁve-point scale:
0 ¼ absent; 1 ¼ mild; 2 ¼ moderate; 3 ¼ severe;
4 ¼ very severe. The total symptom score (TSS)
was calculated by adding the individual symptom
scores, excluding nasal congestion (maximum
possible TSS ¼ 16). For inclusion at visit 1, a
reﬂective TSS ¼ 6, with two or more symptoms
with a minimum score of 2 (moderate), was
necessary. Following visit 1, the studies included
four additional visits: visit 2, randomization (day
1); visit 3, during double-blind treatment (day 6–
10); visit 4, end of double-blind treatment (day
15–17); and visit 5, follow-up (day 22–24).
Following completion of a single-blind, pla-
cebo lead-in period, the children in study I were
required to have a TSS ¼ 5 for the average of the
last two 19:00-hours reﬂective TSS, and patients
in studies II and III required a TSS ¼ 5 for
>60% of the placebo lead-in period to qualify
for randomization to the double-blind phase of
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the study. All children were randomized to
receive either fexofenadine HCl 30 mg b.i.d. or
matching placebo; studies II and III also inclu-
ded doses of 15 and 60 mg b.i.d.. For the purpose
of the present analysis, children treated with
fexofenadine were analyzed in two groups: chil-
dren treated with fexofenadine 30 mg b.i.d. and
children treated with all fexofenadine doses (15,
30 and 60 mg b.i.d.). Safety data corresponding
to the patient groups treated with either 15 or
60 mg b.i.d. fexofenadine HCl are reported
elsewhere (17). Tablets were taken at 19:00 and
7:00 hours (±1 hour) for 2 weeks, with no
dosing instructions regarding food intake.
Throughout the study, SAR symptoms were
assessed daily at 19:00 (±1) hours for the previ-
ous 12-hour period (hereafter referred to as pm
reﬂective) by the subject and caregiver, immedi-
ately prior to dosing.
The individual study protocols were approved
by the appropriate ethics committees.
Safety assessments
Children (and investigators) reported any
adverse events (AEs) during the study. In order
that AE coding was uniform across studies, data
from studies II and III were re-coded using the
Hoechst Adverse Reaction Terminology System
(HARTS) dictionary. Comparison of the original
safety data with the results following recoding
using HARTS showed that this did not have an
eﬀect on the safety proﬁle of fexofenadine, with
the incidence of adverse events and their severity
remaining the same (data not shown). The AE
proﬁles were pooled and presented for the
following treatment groups: fexofenadine HCl
30 mg b.i.d., all fexofenadine-treated subjects
and placebo. Physical examinations, including
vital signs measurements and laboratory tests,
were performed in all three studies. Laboratory
testing was performed on blood samples taken at
visit 1 (screening) and visit 4 (end of treatment)
and included assessments of liver function [alka-
line phosphatase, total bilirubin, lactate dehy-
drogenase (LDH)], renal function (creatinine),
electrolytes (potassium), other chemistry (glu-
cose, triglycerides) and hematology/hemoglobin
(hematocrit, platelet count, white blood cell
count). Study I assessed predeﬁned change
abnormal (PCA) and clinically noteworthy
abnormal laboratory values (CNALVs), whereas
studies II and III assessed outlier values; how-
ever, the values for the ranges of the CNALV
and outliers were similar. In addition, the use of
concomitant medications was also evaluated
during the study. Studies II and III also recorded
results from pre- and post-treatment electro-
cardiograms. These are reported elsewhere (17).
Efficacy measurements
Eﬃcacy of fexofenadine was assessed only in
those children treated with fexofenadine 30 mg
b.i.d. In all three studies, the primary outcome
measures were mean change from baseline in the
average pm reﬂective TSS throughout the double-
blind treatment period and the pm reﬂective
assessment of individual symptom scores. The
only diﬀerence in the studies is the deﬁnition of
baseline TSS. For study I, baseline corresponded
to the average assessment over the last 3 days
prior to the ﬁrst day of study medication; for
studies II and III, baseline corresponded to the
average over the whole placebo lead-in period.
To assess the impact of this diﬀerence, the
baseline for studies II and III was derived using
the average TSS for the last 3 days prior to study
medication. There is a slight decrease in the mean
baseline for the placebo group and no change for
the fexofenadine HCl 30 mg group, indicating
that the alternative methods of calculating base-
line values did not preclude pooling of the three
studies.
Statistical analysis
Children included in the safety evaluations were
required to have been exposed to at least one
dose of the double-blind treatment. Adverse
events recorded by these children were descrip-
tively summarized and no formal statistical
comparisons were made. The eﬃcacy analysis
was undertaken on the modiﬁed intention-to-
treat (mITT) population, which was deﬁned as
all randomized subjects who received at least one
dose of double-blind treatment and had a base-
line and at least one double-blind period pm
reﬂective assessment. Analysis of covariance
(ancova) was used to compare the eﬃcacy of
fexofenadine HCl 30 mg b.i.d. with placebo, and
baseline score was included as a continuous
covariate, with treatment and pool center as ﬁxed
eﬀects. A two-sided 95% conﬁdence interval of
the treatment diﬀerence was derived using adjus-
ted least squares mean from the ancova.
Results
Patient population and demographics
A total of 1810 children were included in the
overall pediatric safety population (placebo,
n ¼ 700; fexofenadine n ¼ 1110). Of these, 673
Safety of oral fexofenadine in children
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children received fexofenadine HCl 30 mg b.i.d.
and 437 children received fexofenadine at doses
of either 15 mg or 60 mg b.i.d. Exposure to
fexofenadine HCl 30 mg b.i.d. and to any fexo-
fenadine dose exceeded 10,000 and 17,000 patient
days, respectively.
The safety populations of the pooled studies
were similar in terms of demographic charac-
teristics (Table 1). For children receiving pla-
cebo or fexofenadine HCl 30 mg b.i.d., 62.2%
of the children were male and the mean age was
8.9 years.
As part of this pooled analysis, eﬃcacy meas-
urements were also determined. A total of 1804
pediatric subjects were evaluable for eﬃcacy and
included in the mITT population (671 children
received fexofenadine HCl 30 mg b.i.d.; 698
children received placebo). There were no
marked diﬀerences in the demographic data of
the mITT population either between studies or
treatment groups. Similarly, within each study,
there was no signiﬁcant diﬀerence in baseline
symptom scores between treatment groups.
Safety assessments
Adverse events. Incidences of AEs, including
discontinuations because of AEs, were low and
comparable across treatment groups in the
pooled analysis (Table 2). In the placebo group,
24.4% (171 of 700) of subjects reported AEs
compared with 24.1% (162 of 673) for fexofen-
adine HCl 30 mg b.i.d., and 28.4% (315 of 1110)
for all fexofenadine-treated (15 mg, 30 mg and
60 mg b.i.d.) children. The most common AE
overall was headache, which occurred in 4.3% of
placebo-treated children, 5.8% of fexofenadine
HCl 30 mg b.i.d.-treated children and in 7.2% of
children treated with either 15, 30 or 60 mg b.i.d.
fexofenadine.
AEs resulted in the withdrawal of six children
receiving fexofenadine HCl 30 mg b.i.d., one
child receiving fexofenadine HCl 15 mg b.i.d.,
one child receiving fexofenadine HCl 60 mg b.i.d.
and ﬁve children receiving placebo. The most
common AE leading to discontinuation was
asthma, which occurred in ﬁve children (three
receiving placebo and two receiving fexofenadine
HCl 30 mg b.i.d.). No AE that resulted in
discontinuation was attributed to study medica-
tion.
The number of treatment-related AEs (poss-
ibly related, probably related or deﬁnitely related
to study treatment) was also comparable between
treatment groups (Table 3). In the placebo
group, a total of 3.4% (24 of 700) of children










































































































































































































































































































































































































































































































































































































































































































































































































































































































































pared with 4.0% (27 of 673) for fexofenadine
HCl 30 mg b.i.d., and 5.2% (58 of 1110) for all
fexofenadine treatment groups. No sedative
eﬀect or other class eﬀects evident with ﬁrst-
generation antihistamines were observed. The
most commonly reported treatment-related AE
was headache, which had an incidence of 1.0%
(7 of 700) for placebo, 1.0% (7 of 673) for
fexofenadine HCl 30 mg b.i.d., and 1.4% (15 of
1110) for all fexofenadine-treated groups. The
majority of the treatment-related AEs were
considered to be of mild or moderate intensity.
The number of children requiring concomitant
medication (i.e. medication that was not provi-
ded in the study protocol) was comparable
between treatment groups. For study I, the
percentage of children taking concomitant medi-
cation was 10.8% (51 of 471) for placebo and
10.3% (48 of 464) for those children treated with
fexofenadine HCl 30 mg. For studies II and III,
the percentage of children taking concomitant
medication was 28.8% (66 of 229) and 24.9%
(161 of 646) for placebo- and fexofenadine-
treated children, respectively.
Two subjects in the three studies reported
serious AEs. One child in study I experienced
neutropenia in the fexofenadine-treated group
(30 mg b.i.d.) on routine evaluation that was
thought to be related to treatment by the
investigator. Laboratory tests revealed decreased
neutrophil levels on day 15 following 14 days of
double-blind treatment (0.4 · 109/l compared
with 2.3 · 109/l at screening). This event was
reported as mild in intensity and the child was
asymptomatic, and recovered without sequelae.
Total leukocyte counts for this child remained
stable during follow-up, but still below the
normal range. Because serologic work was con-
sistent with recent seroconversions forMycoplas-
ma pneumoniae and Varicella IgG, subclinical
infections may oﬀer an alternative explanation
for the event. In addition, in study III, one child
in the 30 mg b.i.d. fexofenadine-treated group
experienced increased asthma and was diagnosed
with status asthmaticus. The investigator felt that
the event was severe, and unlikely to be related to
study medication, and instead related to under-
lying disease with exposure to outdoor allergens
as a trigger.
Vital signs and clinical laboratory evaluations. No
clinically relevant changes were observed in vital
signs data between fexofenadine and placebo-
treated groups.
With the exception of one child with neutrope-
nia described above, in all studies and in all
treatment groups there were no clinically relevant
diﬀerences in laboratory values. In study I, the
most frequently observed PCA and CNALV for
both treatment groups was an increase in eosin-
ophils. In studies II and III, the most frequent
outlier was high hematocrit levels.
Table 2. Most frequently reported adverse events (‡1%) – clinical safety
population






Subjects evaluable for safety
in double-blind period
100 (700) 100 (673) 100 (1110)
Subjects with AEs 24.4 (171) 24.1 (162) 28.4 (315)
Coded Term
Headache 4.3 (30) 5.8 (39) 7.2 (80)
Upper respiratory infection 1.3 (9) 2.1 (14) 2.2 (24)
Cough increased 0.9 (6) 1.6 (11) 1.7 (19)
Epistaxis 1.1 (8) 1.5 (10) 1.5 (17)
Accidental injury 1.6 (11) 1.3 (9) 1.6 (18)
Sore throat 1.6 (11) 1.2 (8) 1.7 (19)
Rash 0.6 (4) 1.2 (8) 1.2 (13)
Nausea 0.1 (1) 1.2 (8) 1.0 (11)
Fever 0.4 (3) 1.0 (7) 1.3 (14)
Sinusitis 0.9 (6) 1.0 (7) 0.8 (9)
Otitis media 0.1 (1) 1.0 (7) 0.8 (9)
Pain 0.3 (2) 0.9 (6) 1.1 (12)
Respiratory disorder 0.7 (5) 0.9 (6) 0.9 (10)
Pharyngitis 0.4 (3) 0.9 (6) 0.9 (10)
Gastrointestinal pain 1.9 (13) 0.7 (5) 1.4 (15)
Vomiting 0.4 (3) 0.7 (5) 0.8 (9)
Dyspepsia 0.1 (1) 0.7 (5) 0.7 (8)
Asthma 2.0 (14) 0.6 (4) 0.5 (5)
Infection 1.9 (13) 0.4 (3) 1.4 (16)
Flu syndrome 0.3 (2) 0.4 (3) 0.6 (7)
Ear pain 0.7 (5) 0.4 (3) 0.5 (5)
Chest pain 0 0.3 (2) 0.5 (5)
Diarrhea 0.1 (1) 0.3 (2) 0.4 (4)
*Fexofenadine HCl at doses of 15, 30 and 60 mg b.i.d.
AE, adverse event.








Subjects evaluable for safety
in double-blind period, % (N)
100 (700) 100 (673) 100 (1110)
Subjects with possibly related
AEs, % (N)
3.4 (24) 4.0 (27) 5.2 (58)
Coded Term
Headache 1.0 (7) 1.0 (7) 1.4 (15)
Gastrointestinal pain 0.6 (4) 0.1 (1) 0.4 (4)
Rash 0.1 (1) 0.3 (2) 0.5 (5)
Insomnia 0 0.1 (1) 0.4 (4)
Somnolence 0.4 (3) 0.1 (1) 0.1 (1)
*Fexofenadine HCl at doses of 15, 30 and 60 mg b.i.d.
AE, adverse event.
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Efficacy assessments
Eﬃcacy analysis showed that fexofenadine HCl
30 mg b.i.d. was signiﬁcantly superior to placebo
in the pm reﬂective TSS pooled analysis
(p £ 0.0001; Fig. 1). The mean change from
baseline was )1.75 for the fexofenadine-treated
group and )1.14 for the placebo group.
In the pooled analysis, all pm reﬂective individ-
ual symptom scores, including nasal congestion,
were signiﬁcantly reduced compared with placebo
(sneezing p £ 0.0001; rhinorrhea p < 0.0058;
itchy nose, mouth, throat and/or ears p £
0.0001; itchy, watery, red eyes p £ 0.0001; nasal
congestion p < 0.0334) (Fig. 2).
Discussion
The safety data from these three pooled studies
showed that over a 2-wk period fexofenadine
HCl (30 mg b.i.d.) is well tolerated, with a
placebo-like safety proﬁle in children with SAR.
The most commonly reported AE was headache,
which occurred with a similar incidence in both
fexofenadine- and placebo-treated groups. The
results of this study also demonstrate that
fexofenadine HCl (30 mg b.i.d.) is eﬀective in
reducing both the TSS and individual symptom
scores of SAR compared with placebo.
The combined results reported here are con-
sistent with the previously published safety data
for fexofenadine studies II and III (17, 18), in
which there were no dose-related trends for AEs
in children. Similar to the present study, the
report by Graft et al. (17) showed that headache
was the most frequently reported AE, with a
similar incidence for all doses of fexofenadine
(15, 30 and 60 mg b.i.d.) compared with placebo.
In addition, early investigation of the clinical
pharmacology of fexofenadine in healthy chil-
dren has shown single doses of 30 and 60 mg are
safe and well-tolerated (19). These ﬁndings are
supported by the established safety proﬁle of
fexofenadine in adults for treatment of allergic
rhinitis (15, 16). The two most commonly repor-
ted AEs in these long-term studies were headache
and viral infection (15, 16). Moreover, since ﬁrst
approved for use in children in 1999, a systematic
review of spontaneous adverse event reports has
not revealed any new risk that could modify the
current safety proﬁle of fexofenadine tablets.
The potential for sedation is important in
terms of safety, and the ability of both adults and
school children to undertake everyday activities.
Superior cognitive functions such as attention,
memory, co-ordination, cognition and psycho-
motor performance may all be aﬀected by
sedation and central nervous system impairment,
with associated safety implications. The ﬁndings
from this study show that no clinically meaning-
ful sedative or other class eﬀects associated with
ﬁrst-generation antihistamines were observed.
These ﬁndings are consistent with studies in
adults, in which fexofenadine, even at doses in
excess of those recommended by the manufac-
turer, did not impair cognitive or psychomotor
function (15, 20, 21). In particular, Hindmarch
and Shamsi (21) conducted a comprehensive
review of published data from well-controlled
trials evaluating the eﬀects of antihistamines on
sedation, psychomotor performance and cogni-
tion in healthy volunteers, using standardized,
quantitative methods determining drug-related
eﬀects. Unlike cetirizine, fexofenadine was not
associated with objective or subjective perform-
ance or cognitive impairment in any test, even at
higher than recommended doses (21). Further-
more, qualitative and quantitative cerebral H1-
binding data from PET studies have shown that
fexofenadine does not bind to the H1-receptor in
the brain, suggesting that it does not cross the
blood–brain barrier, thereby supporting the lack
of somnolence or impairment observed with





























Fig. 1. Mean (±s.e.) change in pm reﬂective TSS with
mITT population; p £ 0.0001 vs. placebo (for children




































Fig. 2. Reﬂective individual symptom scores with mITT
population. *p < 0.05, **p < 0.01, ***p £ 0.0001 vs.




A number of reports have linked some anti-
histamines to prolongation of the QT interval
corrected for heart rate (QTc) interval when
administered in the presence of hepatic impair-
ment or with drugs that inhibit the cytochrome
P450 hepatic enzyme system. Electrocardiograms
were performed in studies II and III, and showed
that fexofenadine has no eﬀect on the QTc (17).
Other studies, conducted in children and adults
with SAR, in healthy children and adults, and in
drug interaction studies with ketoconazole and
erythromycin, also showed no eﬀect of fexofen-
adine on the QTc compared with placebo (15, 17,
20, 23). Furthermore, the cardiovascular safety
of fexofenadine in adults has been established at
daily doses up to 690 mg b.i.d. (24).
Traditionally, antihistamines have not been
considered to be eﬀective in relieving nasal
congestion (25–27) and, accordingly, second-
generation antihistamines are not indicated for
this purpose. The results of this pooled analysis
shows that fexofenadine HCl (30 mg b.i.d.) is
eﬀective in reducing both the TSS and all
individual symptoms, including nasal congestion,
in children with SAR. These results are consis-
tent with the recently published eﬃcacy data
from one of the studies reported here, in which
fexofenadine was shown to be eﬃcacious across
all symptoms of SAR (18). Similarly, other
studies in adults with SAR have shown signiﬁ-
cant eﬃcacy with fexofenadine in relieving all
symptoms of SAR, including nasal congestion
(10, 12, 14). It is hypothesized that the ability of
certain antihistamines, such as fexofenadine, to
inhibit the late-phase response may be attribut-
able in part to anti-inﬂammatory eﬀects that are
not necessarily directly related to H1-receptor
antagonism (28–30).
Conclusion
The results from this pooled analysis of three
clinical studies show that fexofenadine HCl at
doses of 15, 30 and 60 mg b.i.d. is safe and well
tolerated in children aged 6–11 years over a
period of 2 weeks. In this large pediatric popula-
tion, fexofenadine is also eﬀective at relieving all
symptoms of SAR, including nasal congestion.
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